- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07595302
Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain (PIVOTAL)
Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain: A Randomized, Double-Blind, Double-Dummy Controlled Trial (PIVOTAL Trial)
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
An estimated 70% of Emergency Department (ED) visits involve pain as a complaint. Although ED practice has shifted away from routine opioid prescribing, uncertainty remains regarding optimal selection among commonly used non-opioid analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. Medication selection varies by pain etiology, and among patients presenting with musculoskeletal pain, opioids (40.7%), acetaminophen (37.8%), and NSAIDs (22.6%) remain the most frequently administered medications in the ED.
Pain in women has been comparatively understudied. Pelvic pain is common among women of childbearing age, and chronic pelvic pain affects up to 24% of women overall. In nonpregnant women, NSAIDs are widely considered first-line therapy for both acute and chronic pelvic pain. In pregnant women and in those attempting to conceive, NSAIDs are typically avoided. Observational studies have associated NSAID use around the time of conception or prior to 20 weeks' gestation with an increased risk of miscarriage, while acetaminophen has not shown a similar association. NSAID exposure in early pregnancy has also been linked to congenital anomalies.
Guidelines recommend limiting opioid use during pregnancy and in women of childbearing age. Opioid exposure has been associated with congenital anomalies and with poorer maternal and neonatal outcomes. As a result, opioids are generally avoided as first-line therapy for pelvic pain in patients who are pregnant or may be pregnant.
Therefore, it is routine to ascertain pregnancy status prior to administering NSAIDs or opioids to women of childbearing age for an informed decision making discussion. Acetaminophen, in contrast, is generally considered safe in pregnancy and can be administered without delay while awaiting pregnancy testing. Acetaminophen is associated with relatively mild side effects, which may vary by route of administration.
Pharmacokinetic studies demonstrate that intravenous acetaminophen achieves higher peak plasma concentrations and faster central nervous system penetration than oral administration. Outside the ED, IV acetaminophen has been associated with faster onset of meaningful pain relief and reduced opioid use in some surgical populations. Whether these pharmacologic advantages translate into clinically meaningful improvements in acute pelvic pain management in the Emergency Department for patients of childbearing potential with pelvic pain is unclear.
The investigator team hypothesizes that among women aged 16-50 presenting to the emergency department with pelvic pain, patients receiving intravenous acetaminophen will achieve a greater improvement in the numeric rating scale (NRS) pain score at 30 minutes compared with oral acetaminophen.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 4
Contactos e Locais
Contato de estudo
- Nome: Mustfa Manzur, MD MPH MS
- Número de telefone: 718-920-6674
- E-mail: mmanzur@montefiore.org
Locais de estudo
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
Contato:
- Mustfa Manzur, MD MPH MS
- Número de telefone: 718-920-6626
- E-mail: mmanzur@montefiore.org
-
Investigador principal:
- Eddie M Irizarry, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Filho
- Adulto
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Female sex at birth
- Presentation to the Emergency Department (ED) with pelvic pain
- Baseline numeric pain score (NRS) ≥4
- Ability to provide informed consent in English or Spanish
Exclusion Criteria:
- Receipt of any analgesic medication within 2 hours or acetaminophen within 6 hours
- Known allergy or intolerance to acetaminophen
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Oral Drug + IV Placebo
Oral Acetaminophen 1000mg + IV placebo Oral Acetaminophen 1000mg No additional analgesics will be administered prior to two hours unless clinically indicated. Rescue analgesia may be administered at any time at the discretion of the treating clinician. |
Oral Acetaminophen 1000mg
IV placebo administration
|
|
Comparador Ativo: Intravenous Drug + Oral Placebo
Intravenous Acetaminophen + PO placebo IV Acetaminophen 1000mg No additional analgesics will be administered prior to two hours unless clinically indicated. Rescue analgesia may be administered at any time at the discretion of the treating clinician. |
Intravenous Acetaminophen 1000mg
Oral placebo administration
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean Change in Numeric Rating Scale (NRS) score
Prazo: From baseline to 30 minutes following medication administration
|
Mean Change in NRS score will be assessed at 30 minutes post-treatment.
The NRS is a patient self-assessment pain scale that instructs patients to use a facial grimace scale ranging from 0-10 rating to express pain intensity, wherein 0 is "No pain" and 10 is "Worst pain possible," such that higher scores are indicative of greater pain intensity.
For purposes of the primary outcome change in NRS score from baseline will be assessed.
Results will be summarized by study arm using descriptive statistics.
|
From baseline to 30 minutes following medication administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain Intensity
Prazo: 0-, 5-, 10-, 15-, 30-, 45-, 60- and 120-minutes following medication administration
|
Participants will be asked to serially assess their current level of pain intensity as either "Severe," "Moderate," "Mild," or "None."
Categorical assessments of pain intensity will be summarized by study arm at each prespecified timepoint.
|
0-, 5-, 10-, 15-, 30-, 45-, 60- and 120-minutes following medication administration
|
|
Time to Clinically Meaningful Reduction in Pain
Prazo: Within 2 hours after medication administration
|
Time to clinically meaningful pain reduction as assessed by the Numerical Rating Scale (NRS).
The NRS is a pain scale that uses a 0-10 rating to measure pain intensity, where 0 is "No pain" and 10 is "Worst pain possible."
Clinically meaningful pain reduction will be defined as achieving a reduction in NRS score of ≥1.3 from baseline.
Results will be summarized by study arm using basic descriptive statistics.
|
Within 2 hours after medication administration
|
|
Use of Rescue Medications
Prazo: Within 2 hours following medication administration
|
The number/percentage of patients requiring rescue analgesia of any type within 120 minutes will be summarized by study arm using basic descriptive statistics.
|
Within 2 hours following medication administration
|
|
Patient Global Impression of Change (PGI-C) Score
Prazo: 30- and 120-minutes following medication administration
|
Effectiveness of treatment will be evaluated using the PGI-C scale.
The PGI-C scale is a 7-point self-reported scale used to assess the patient's perception of change in condition/health status following treatment.
Patients will provide a single response as to their self-perception of change in condition/health status on a scale ranging from 1 ("Very much improved") to 7 ("Very much worse)" with 4 representing "No change" as the midpoint.
Lower scores are indicative of an improved self-assessment of condition following treatment.
Scores will be summarized by study arm using descriptive statistics.
|
30- and 120-minutes following medication administration
|
|
Treatment-Related Adverse Events (TRAEs)
Prazo: Within 2 hours following medication administration
|
All treatment-related adverse events occurring within 2 hours of medication administration will be recorded and summarized by study arm.
|
Within 2 hours following medication administration
|
|
Emergency Department (ED) Disposition
Prazo: At 2 hours following medication administration
|
ED disposition will be summarized at 2 hours.
Patients will be categorized as either having been admitted, discharged, or status yet to be determined.
Categorical data will be summarized by study arm.
|
At 2 hours following medication administration
|
|
Length of Stay (LOS)
Prazo: Less than 24 hours following medication administration
|
Length of stay will be determined based on the time interval between arrival in the ED and disposition determination.
Mean LOS will be summarized by study arm.
|
Less than 24 hours following medication administration
|
|
Patient Satisfaction
Prazo: At 2 hours following medication administration
|
Patient satisfaction will be determined by asking patients whether they would prefer the same medication which was administered during the study if they returned to the ED with the same condition.
The number/percentage of patients who prefer the same medication will be summarized by study arm.
|
At 2 hours following medication administration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Eddie M Irizarry, MD, Montefiore Medical Center
Publicações e links úteis
Publicações Gerais
- Latthe P, Latthe M, Say L, Gulmezoglu M, Khan KS. WHO systematic review of prevalence of chronic pelvic pain: a neglected reproductive health morbidity. BMC Public Health. 2006 Jul 6;6:177. doi: 10.1186/1471-2458-6-177.
- Cordell WH, Keene KK, Giles BK, Jones JB, Jones JH, Brizendine EJ. The high prevalence of pain in emergency medical care. Am J Emerg Med. 2002 May;20(3):165-9. doi: 10.1053/ajem.2002.32643.
- Li DK, Liu L, Odouli R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study. BMJ. 2003 Aug 16;327(7411):368. doi: 10.1136/bmj.327.7411.368.
- Moller PL, Sindet-Pedersen S, Petersen CT, Juhl GI, Dillenschneider A, Skoglund LA. Onset of acetaminophen analgesia: comparison of oral and intravenous routes after third molar surgery. Br J Anaesth. 2005 May;94(5):642-8. doi: 10.1093/bja/aei109. Epub 2005 Mar 24.
- Antonucci R, Zaffanello M, Puxeddu E, Porcella A, Cuzzolin L, Pilloni MD, Fanos V. Use of non-steroidal anti-inflammatory drugs in pregnancy: impact on the fetus and newborn. Curr Drug Metab. 2012 May 1;13(4):474-90. doi: 10.2174/138920012800166607.
- Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy. Obstet Gynecol. 2017 Aug;130(2):e81-e94. doi: 10.1097/AOG.0000000000002235.
- Interrante JD, Ailes EC, Lind JN, Anderka M, Feldkamp ML, Werler MM, Taylor LG, Trinidad J, Gilboa SM, Broussard CS; National Birth Defects Prevention Study. Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011. Ann Epidemiol. 2017 Oct;27(10):645-653.e2. doi: 10.1016/j.annepidem.2017.09.003. Epub 2017 Sep 20.
- Gottlieb M, Bernard K. Epidemiology of back pain visits and medication usage among United States emergency departments from 2016 to 2023. Am J Emerg Med. 2024 Aug;82:125-129. doi: 10.1016/j.ajem.2024.06.020. Epub 2024 Jun 15.
- Singla NK, Parulan C, Samson R, Hutchinson J, Bushnell R, Beja EG, Ang R, Royal MA. Plasma and cerebrospinal fluid pharmacokinetic parameters after single-dose administration of intravenous, oral, or rectal acetaminophen. Pain Pract. 2012 Sep;12(7):523-32. doi: 10.1111/j.1533-2500.2012.00556.x. Epub 2012 Apr 24.
- van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD. Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther. 1988 Dec;247(3):1233-9.
- Yazdy MM, Mitchell AA, Tinker SC, Parker SE, Werler MM. Periconceptional use of opioids and the risk of neural tube defects. Obstet Gynecol. 2013 Oct;122(4):838-844. doi: 10.1097/AOG.0b013e3182a6643c.
- Shah S, Banh ET, Koury K, Bhatia G, Nandi R, Gulur P. Pain Management in Pregnancy: Multimodal Approaches. Pain Res Treat. 2015;2015:987483. doi: 10.1155/2015/987483. Epub 2015 Sep 13.
- Juganavar A, Joshi KS. Chronic Pelvic Pain: A Comprehensive Review. Cureus. 2022 Oct 26;14(10):e30691. doi: 10.7759/cureus.30691. eCollection 2022 Oct.
- Hansen RN, Pham AT, Boing EA, Lovelace B, Wan GJ, Miller TE. Comparative analysis of length of stay, hospitalization costs, opioid use, and discharge status among spine surgery patients with postoperative pain management including intravenous versus oral acetaminophen. Curr Med Res Opin. 2017 May;33(5):943-948. doi: 10.1080/03007995.2017.1297702. Epub 2017 Mar 9.
- Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U. Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf. 2006;29(5):397-419. doi: 10.2165/00002018-200629050-00004.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 2025-17368
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Acetaminophen 1000mg PO
-
Priovant Therapeutics, Inc.Ativo, não recrutandoUveíte | Uveíte Posterior | Uveíte, IntermediáriaEstados Unidos, Espanha, Alemanha, Itália, Israel, Austrália, Argentina, Áustria, Bélgica, Tcheca, Grécia, Hungria, Reino Unido
-
Thammasat UniversityAinda não está recrutandoAnalgesia Pós Operatória | Amigdalectomia com ou sem adenoidectomiaTailândia
-
Dong-A ST Co., Ltd.ConcluídoSaudávelRepublica da Coréia
-
Merck KGaA, Darmstadt, GermanyConcluído
-
Dong-A ST Co., Ltd.ConcluídoSaudávelRepublica da Coréia
-
Dong-A ST Co., Ltd.Ainda não está recrutandoSaudávelRepublica da Coréia
-
Dong-A ST Co., Ltd.Ainda não está recrutandoSaudávelRepublica da Coréia
-
Toll Biotech Co. Ltd. (Beijing)RecrutamentoArtrite Reumatoide (AR)China
-
AfimmuneRescindidoHepatite Alcoólica Aguda Grave DescompensadaEstados Unidos, Geórgia
-
PATHBill and Melinda Gates Foundation; UNITAIDRecrutamentoFoco do estudo: Medição e diagnóstico clínico precisoQuênia